ARQT vs. CAMT
ARQT (Arcutis Biotherapeutics, Inc.) and CAMT (Camtek Ltd.) are both stocks. ARQT operates in Biotechnology (Healthcare), while CAMT operates in Semiconductor Equipment & Materials (Technology). Over the past 5 years, ARQT returned 2.86%/yr vs 29.20%/yr for CAMT. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
ARQT vs. CAMT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARQT achieves a -7.51% return, which is significantly lower than CAMT's 24.56% return.
ARQT
- 1D
- -4.04%
- 1M
- 4.07%
- 6M
- 5.87%
- YTD
- -7.51%
- 1Y
- 87.96%
- 3Y*
- 36.46%
- 5Y*
- 2.86%
- 10Y*
- —
- ALL TIME*
- 2.38%
CAMT
- 1D
- -3.48%
- 1M
- -7.05%
- 6M
- -9.60%
- YTD
- 24.56%
- 1Y
- 38.70%
- 3Y*
- 41.97%
- 5Y*
- 29.20%
- 10Y*
- 48.82%
- ALL TIME*
- 12.66%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $31.41M | $36.97M | $43.61M | |
CAMT Camtek Ltd. | $71.36M | $73.47M | $86.04M |
ARQT vs. CAMT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | -7.51% | 108.47% | 331.27% | -78.18% | -28.64% | -26.27% | 22.04% |
CAMT Camtek Ltd. | 24.56% | 31.66% | 18.33% | 215.94% | -52.30% | 110.13% | 85.52% |
Correlation
The correlation between ARQT and CAMT is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.15 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 2020 | 0.21 |
Fundamentals
ARQT:
$3.36B
CAMT:
$6.18B
ARQT:
-$0.02
CAMT:
$0.98
ARQT:
8.57
CAMT:
13.02
ARQT:
18.32
CAMT:
9.99
ARQT:
$415.62M
CAMT:
$499.09M
ARQT:
$377.98M
CAMT:
$250.68M
ARQT:
$12.21M
CAMT:
$122.77M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARQT vs. CAMT — Risk / Return Rank
ARQT
CAMT
ARQT vs. CAMT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Camtek Ltd. (CAMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARQT | CAMT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.88 | ||
| Sortino ratioReturn per unit of downside risk | +1.05 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.15 | +0.13 |
| Calmar ratioReturn relative to maximum drawdown | 2.26 | 1.05 | +1.20 |
| Martin ratioReturn relative to average drawdown | 5.02 | 2.82 | +2.20 |
Loading charts...
Drawdowns
ARQT vs. CAMT - Drawdown Comparison
The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum CAMT drawdown of -97.71%. Use the drawdown chart below to compare losses from any high point for ARQT and CAMT.
Loading charts...
Drawdown Indicators
| ARQT | CAMT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.02% | -97.71% | +2.69% |
Max Drawdown (1Y)Largest decline over 1 year | -37.50% | -38.80% | +1.30% |
Max Drawdown (3Y)Largest decline over 3 years | -81.28% | -63.16% | -18.12% |
Max Drawdown (5Y)Largest decline over 5 years | -93.17% | -63.16% | -30.01% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.16% | — |
Current DrawdownCurrent decline from peak | -27.37% | -36.15% | +8.78% |
Average DrawdownAverage peak-to-trough decline | -49.60% | -55.55% | +5.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.82% | 14.47% | +2.35% |
Volatility
ARQT vs. CAMT - Volatility Comparison
The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 12.05%, while Camtek Ltd. (CAMT) has a volatility of 24.11%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than CAMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARQT | CAMT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.05% | 24.11% | -12.06% |
Volatility (6M)Calculated over the trailing 6-month period | 37.39% | 56.30% | -18.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.52% | 69.56% | -12.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.75% | 57.22% | +14.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 76.34% | 52.78% | +23.56% |
Dividends
ARQT vs. CAMT - Dividend Comparison
Neither ARQT nor CAMT has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CAMT Camtek Ltd. | 0.00% | 0.00% | 1.65% | 0.00% | 0.00% | 0.00% | 0.00% | 1.57% | 2.07% | 2.45% |
Financials
ARQT vs. CAMT - Financials Comparison
This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Camtek Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ARQT vs. CAMT - Profitability Comparison
ARQT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 95.61M and revenue of 105.40M. Therefore, the gross margin over that period was 90.7%.
CAMT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Camtek Ltd. reported a gross profit of 60.93M and revenue of 121.66M. Therefore, the gross margin over that period was 50.1%.
ARQT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Arcutis Biotherapeutics, Inc. reported an operating income of -9.09M and revenue of 105.40M, resulting in an operating margin of -8.6%.
CAMT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Camtek Ltd. reported an operating income of 27.27M and revenue of 121.66M, resulting in an operating margin of 22.4%.
ARQT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Arcutis Biotherapeutics, Inc. reported a net income of -11.30M and revenue of 105.40M, resulting in a net margin of -10.7%.
CAMT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Camtek Ltd. reported a net income of 31.65M and revenue of 121.66M, resulting in a net margin of 26.0%.
Frequently Asked Questions
ARQT and CAMT have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CAMT has higher volatility (24.11%) compared to ARQT (12.05%). In terms of maximum drawdown, ARQT dropped -95.02% vs CAMT's -97.71%.
ARQT currently has the higher Sharpe Ratio (1.47 vs 0.59), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARQT and CAMT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer